Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors - Lertkhachonsuk - 2020 - Journal of Obstetrics and Gynaecology Research - Wiley Online Library
Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients
Ovarian tumor markers: What to draw and when | MDedge ObGyn
CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube
Tumor markers
CA 125, CA 15-3, CA 19-9 and CEA assay values during the three... | Download Table
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
CA19-9 for detecting recurrence of pancreatic cancer | Scientific Reports
PDF) CA 19-9 is more useful than CA 125 in the diagnosis of ovarian malignancy, and can truly differentiate the histological subtypes of the ovarian tumours
IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite
Markedly elevated CA19-9 associated with benign ovarian cyst and ascites | BMJ Case Reports
Diseases | Free Full-Text | Diagnostic and Prognostic Value of CEA and CA19- 9 in Colorectal Cancer
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
Clinical analysis of four serum tumor markers in 458 patients with ova | CMAR
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
Cancers | Free Full-Text | CA125 and Ovarian Cancer: A Comprehensive Review
Clinical analysis of four serum tumor markers in 458 patients with ova | CMAR
Clinical Utility of Tumor Markers
Review of Ovarian Tumors in Children and Adolescents: Radiologic-Pathologic Correlation | RadioGraphics
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma | PLOS ONE
Introduction and overview of CA19-9 CA19-9 is a tumour associated antigen found in the blood serum. CA 19-9 is also known as the Sialylated Lewis-antigen. - ppt download
Pancreatic Cancer Tumor Markers | GeneTex
